PMID- 34964782
OWN - NLM
STAT- MEDLINE
DCOM- 20220131
LR  - 20230103
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 100
IP  - 47
DP  - 2021 Nov 24
TI  - Network pharmacology-based strategy to investigate the active ingredients and 
      molecular mechanisms of Scutellaria Barbata D. Don against radiation pneumonitis.
PG  - e27957
LID - 10.1097/MD.0000000000027957 [doi]
LID - e27957
AB  - INTRODUCTION: Herbal medicines combined with radiotherapy significantly reduced 
      the incidence of radiation pneumonitis (RP), and the Scutellaria barbata D. Don 
      (SBD) is a perennial herb that has been reported to protect against 
      radiation-induced pneumonitis. However, the exact molecular mechanism is not 
      known. The objective of this research was to investigate the against radiation 
      pneumonitis ingredients and their functional mechanisms in SBD. METHODS: Based on 
      the network pharmacology approaches, we collected active ingredients and target 
      genes in SBD against RP through Traditional Chinese Medicine System Pharmacology 
      (TCMSP) Database, and the "Herb-Ingredients-Target Genes-Disease" Network was 
      constructed by using of Cytoscape. STRING analysis was performed to reveal the 
      protein-protein interactions, and then we applied enrichment analysis on these 
      target proteins, gene function, and pathways. RESULTS: A total of 18 ingredients 
      in SBD regulate 65 RP related target proteins, which show that quercetin, 
      luteolin, baicalein, wogonin may be the key active ingredients, while IL6, AKT1, 
      VEGFA, MMP9, CCL2, prostaglandin-endoperoxide synthase 2 (PTGS2) 
      (cyclooxygenase-2 [COX-2]), CXCL8, IL1B, mitogen-activated protein kinase 
      (MAPK1), and IL10 were identified as critical targets. Besides, the results of 
      Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and 
      Genomes (KEGG) pathway enrichment analysis indicated that predicted targets of 
      SBD are mostly associated with the pathological process of oxidative stress and 
      inflammation. AGE- Receptor of Advanced Glycation Endproducts (RAGE) signaling 
      pathway in diabetic complications, IL-17 signaling pathway, hypoxia-inducible 
      factor-1 (HIF-1) signaling pathway, NF-kappa B signaling pathway might serve as 
      the principal pathways for RP treatment. CONCLUSION: In our study, the 
      pharmacological and molecular mechanism of SBD against RP was predicted from a 
      holistic perspective, and the results provided theoretical guidance for 
      researchers to explore the mechanism in further research.
CI  - Copyright (c) 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Sun, Ping-Yi
AU  - Sun PY
AUID- ORCID: 0000-0002-5694-1083
AD  - Shandong University of Traditional Chinese Medicine, Jinan 250000, China.
FAU - Wang, Ai-Shuai
AU  - Wang AS
AD  - Department of Traditional Chinese Medicine, The First Affiliated Hospital of 
      Shandong First Medical University, Jinan 250000, China.
FAU - Zhang, Zhen-Fei
AU  - Zhang ZF
AD  - Heze Hospital of traditional Chinese Medicine, Heze 274000, China.
FAU - Zhang, Yan-Li
AU  - Zhang YL
AD  - Shandong University of Traditional Chinese Medicine, Jinan 250000, China.
FAU - Zheng, Xin
AU  - Zheng X
AD  - Qingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser hospital), 
      Qingdao 266000, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - *Drugs, Chinese Herbal
MH  - Humans
MH  - Medicine, Chinese Traditional
MH  - Network Pharmacology
MH  - *Radiation Pneumonitis/therapy
MH  - *Scutellaria
PMC - PMC8615305
COIS- The authors have no funding and conflicts of interests to disclose.
EDAT- 2021/12/30 06:00
MHDA- 2022/02/01 06:00
PMCR- 2021/11/24
CRDT- 2021/12/29 12:22
PHST- 2021/05/30 00:00 [received]
PHST- 2021/11/05 00:00 [accepted]
PHST- 2021/12/29 12:22 [entrez]
PHST- 2021/12/30 06:00 [pubmed]
PHST- 2022/02/01 06:00 [medline]
PHST- 2021/11/24 00:00 [pmc-release]
AID - 00005792-202111240-00057 [pii]
AID - MD-D-21-03835 [pii]
AID - 10.1097/MD.0000000000027957 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2021 Nov 24;100(47):e27957. doi: 
      10.1097/MD.0000000000027957.